Study S002331

A Multiple Dose Human Tolerability and Pharmacokinetic Study of IBI362 in Chinese Patients With Type 2 Diabetes Mellitus and Poor Glycemic Control

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT04466904
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 42
Start: 2020-09-12
Primary completion: 2021-05-28
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:IBI362; DRUG:Placebo; DRUG:Dulaglutide
Results posted: FALSE

Registered primary outcomes

To assess the number and incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of IBI362 compared with placebo [From the first dose of study drug to week 19]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0009340	A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Jiang H, Nature communications	2022	Randomized trial	PMID 35750681 DOI	cites ClinicalTrials.gov:NCT04466904; registry reference DERIVED:35750681